Montana enacted a sweeping new regulatory framework this week that fast-tracks experimental drugs to patients before completing standard FDA approval phases. The state law allows biotech companies to offer medications that have passed only preliminary testing, sometimes involving as few as 10 participants, directly to residents with terminal illnesses.
The move positions Montana as a test case for "right-to-try" expansion beyond current federal protections. Traditional FDA approval requires Phase 1, 2, and 3 clinical trials spanning years and involving thousands of participants. Montana's framework compresses this timeline dramatically, letting patients access treatments during early development stages when safety data remains limited.
Supporters argue the law addresses a real problem: terminally ill patients exhaust approved options and face bureaucratic delays accessing experimental therapies. They contend patients should control their own medical decisions when facing death. Biotech companies gain accelerated pathways to real-world feedback and potential revenue before full FDA clearance.
The regulatory gamble carries serious risks. Preliminary-stage drugs frequently fail in later trials or cause unexpected harm. Patients lack the statistical protection that larger trials provide. Limited safety monitoring could produce adverse events with inadequate reporting mechanisms. The framework also raises questions about informed consent when experimental data is sparse.
Other states are watching Montana closely. Success could trigger a cascade of similar programs, fragmenting drug regulation across the country. Failure, particularly if patients experience preventable harm, could spark backlash against right-to-try expansion nationally.
Montana's experiment reflects genuine tension in medical regulation: protecting patients from exploitation versus respecting autonomy at life's end. The framework tests whether compressed timelines can responsibly serve desperate patients without sacrificing safety oversight. The state becomes a real-world laboratory for how far biotech development can accelerate before evidence maturity becomes genuinely dangerous. Results will shape whether other states follow or regulators tighten standards nationally.